FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF
申请人:Sarepta Therapeutics, Inc.
公开号:US20140330006A1
公开(公告)日:2014-11-06
Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
Total Synthesis of the Cyclic Depsipeptide YM-280193, a Platelet Aggregation Inhibitor
作者:Harveen Kaur、Paul W. R. Harris、Peter J. Little、Margaret A. Brimble
DOI:10.1021/ol503507g
日期:2015.2.6
first total synthesis of YM-280193, a cyclic depsipeptide that inhibits the ADP-induced aggregation of human platelets, is described. The monomer and dipeptide fragments were prepared using conventional chemistry and subsequently assembled by Fmoc-solid-phase peptide synthesis (Fmoc-SPPS). A late-stage novel bis-alkylation–elimination of cysteine on-resin was employed to introduce the unnatural N-methyldehydroalanine
Native Chemical Ligation of Thioamide-Containing Peptides: Development and Application to the Synthesis of Labeled α-Synuclein for Misfolding Studies
作者:Solongo Batjargal、Yanxin J. Wang、Jacob M. Goldberg、Rebecca F. Wissner、E. James Petersson
DOI:10.1021/ja2113245
日期:2012.6.6
Thioamide modifications of the peptide backbone are used to perturb secondary structure, to inhibit proteolysis, as photoswitches, and as spectroscopic labels. Thus far, their incorporation has been confined to single peptides synthesized on solid phase. We have generated thioamides in C-terminal thioesters or N-terminal Cys fragments and examined their compatibility with native chemical ligation conditions
肽主链的硫代酰胺修饰用于扰乱二级结构、抑制蛋白水解、作为光开关和光谱标记。到目前为止,它们的掺入仅限于固相合成的单一肽。我们在 C 端硫酯或 N 端 Cys 片段中生成了硫代酰胺,并检查了它们与天然化学连接条件的相容性。大多数序列变体可以与 TCEP 或 DTT 作为还原剂以良好的产率偶联,但在延长 TCEP 孵育时观察到一些副产物。此外,我们发现硫代酰胺与 N 末端 Cys 的噻唑烷保护相容,因此可以使用多重连接来构建更大的蛋白质。由于硫代酰胺的酸不稳定性阻碍了使用 Boc 化学在树脂上合成硫酯,因此我们设计了一种合成硫代酰胺肽的方法,该方法具有原位显示的掩蔽 C 末端硫酯。最后,我们证明,通过合成用于蛋白质折叠研究的淀粉样蛋白 α-突触核蛋白的标记版本,硫代酰胺肽可以与表达的蛋白质片段偶联,生成带有主链硫代酰胺标记的大蛋白质。在原理验证实验中,我们证明硫代酰胺的荧光猝灭可用于跟踪标记的
[EN] RAS BINDING PEPTIDES AND METHODS OF USE<br/>[FR] PEPTIDES DE LIAISON À RAS ET MÉTHODES D'UTILISATION
申请人:RA PHARMACEUTICALS INC
公开号:WO2017181061A1
公开(公告)日:2017-10-19
The present invention provides Ras modulators including inhibitors and/or antagonists of Ras, Ras binding, and Ras-dependent cell signaling activity. Also provided are methods of utilizing the Ras modulators as therapeutics.
[EN] HYDROGELS WITH BIODEGRADABLE CROSSLINKING<br/>[FR] HYDROGELS À RÉTICULATION BIODÉGRADABLE
申请人:PROLYNX LLC
公开号:WO2013036847A1
公开(公告)日:2013-03-14
Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals. This invention provides hydrogels that degrade to smaller, soluble components in a non-enzymatic process upon exposure to physiological conditions and to methods to prepare them. The hydrogels are prepared from crosslinking agents that undergo elimination reactions under physiological conditions, thus cleaving the crosslinking agent from the backbone of the hydrogel. The invention also relates to the crosslinking agents themselves and intermediates in forming the hydro gels of the invention. The biodegradable hydro gels prepared according to the methods of the invention may be of use in diverse fields, including biomedical engineering, absorbent materials, and as carriers for drug delivery.